

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
8 January 2009 (08.01.2009)

PCT

(10) International Publication Number
WO 2009/004427 A3

(51) International Patent Classification:

C07D 401/04 (2006.01) **C07D 413/14** (2006.01)
C07D 401/12 (2006.01) **C07D 471/04** (2006.01)
C07D 401/14 (2006.01) **A61K 31/4433** (2006.01)
C07D 403/04 (2006.01) **A61K 31/4439** (2006.01)
C07D 403/14 (2006.01) **A61K 31/517** (2006.01)
C07D 405/14 (2006.01) **A61P 35/00** (2006.01)
C07D 409/14 (2006.01)

(US). **REITER, Lawrence, Alan** [US/US]; 32 West Mystic Avenue, Mystic, Connecticut 06355 (US).(74) **Agents: FULLER, Grover F. Jr.** et al.; c/o George, Nancy, McGraw, Pfizer Inc. MS8260-1615, Eastern Point Road, Groton, Connecticut 06340 (US).

(21) International Application Number:

PCT/IB2008/001575

(22) International Filing Date: 16 June 2008 (16.06.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/947,287 29 June 2007 (29.06.2007) US
 61/041,645 2 April 2008 (02.04.2008) US

(71) **Applicant (for all designated States except US): PFIZER INC.** [US/US]; 235 East 42nd Street, New York, New York 10017 (US).

(72) Inventors; and

(75) **Inventors/Applicants (for US only): JONES, Christopher, Scott** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340 (US). **LA GRECA, Susan** [US/US]; 1 Longacre Lane, Old Lyme, Connecticut 06371 (US). **LI, Qifang** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, Connecticut 06340 (US). **MUNCHHOF, Michael, John** [US/US]; Pfizer Global Research & Development, Eastern Point Road, Groton, Connecticut 06340

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) **Date of publication of the international search report:**

4 June 2009

(54) **Title:** BENZIMIDAZOLE DERIVATIVES

(I)

(57) Abstract: The present invention relates to a compound of the Formula I (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3A, R3B, R4, R5, X, m, and n are as defined herein. Such novel benzimidazole derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.